Direct in vivo gene therapy has been used in Spinal Muscular Atrophy (SMA) treatment, where the SMN1 gene is delivered using an AAV9 vector, targeting motor neurons directly. The gene discussed is SMN1; the disease is spinal muscular atrophy.